Immunotherapy and biological modifiers for the treatment of malignant brain tumors

Carlo Marras, Carmela Mendola, Federico Giuseppe Legnani, Francesco DiMeco

Research output: Contribution to journalArticle

Abstract

The relative ineffectiveness of current therapies for malignant gliomas has led to the need for novel therapeutics. Therapies based on biologic modifiers are among a variety of cancer treatments currently in use or under experimental evaluation and have shown great promise, especially since several potent stimulators of the immune system have been cloned and are now available for clinical use. Early attempts at glioma therapy based on biologic modifiers, however, have failed to demonstrate significant effectiveness. In this review, we select and summarize the results of preclinical and clinical studies published during the past two years that focus on immunotherapy and biologic modifiers for treating gliomas. Despite limited clinical success, we conclude that an increased understanding of molecular biology and immunology from recent studies may pave the way for more effective approaches.

Original languageEnglish (US)
Pages (from-to)204-208
Number of pages5
JournalCurrent Opinion in Oncology
Volume15
Issue number3
DOIs
StatePublished - May 2003

Fingerprint

Brain Neoplasms
Immunotherapy
Glioma
Therapeutics
Allergy and Immunology
Molecular Biology
Immune System
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Immunotherapy and biological modifiers for the treatment of malignant brain tumors. / Marras, Carlo; Mendola, Carmela; Legnani, Federico Giuseppe; DiMeco, Francesco.

In: Current Opinion in Oncology, Vol. 15, No. 3, 05.2003, p. 204-208.

Research output: Contribution to journalArticle

Marras, Carlo ; Mendola, Carmela ; Legnani, Federico Giuseppe ; DiMeco, Francesco. / Immunotherapy and biological modifiers for the treatment of malignant brain tumors. In: Current Opinion in Oncology. 2003 ; Vol. 15, No. 3. pp. 204-208.
@article{c3455213d0f94eb8aad0b09c7d8b72cb,
title = "Immunotherapy and biological modifiers for the treatment of malignant brain tumors",
abstract = "The relative ineffectiveness of current therapies for malignant gliomas has led to the need for novel therapeutics. Therapies based on biologic modifiers are among a variety of cancer treatments currently in use or under experimental evaluation and have shown great promise, especially since several potent stimulators of the immune system have been cloned and are now available for clinical use. Early attempts at glioma therapy based on biologic modifiers, however, have failed to demonstrate significant effectiveness. In this review, we select and summarize the results of preclinical and clinical studies published during the past two years that focus on immunotherapy and biologic modifiers for treating gliomas. Despite limited clinical success, we conclude that an increased understanding of molecular biology and immunology from recent studies may pave the way for more effective approaches.",
author = "Carlo Marras and Carmela Mendola and Legnani, {Federico Giuseppe} and Francesco DiMeco",
year = "2003",
month = "5",
doi = "10.1097/00001622-200305000-00004",
language = "English (US)",
volume = "15",
pages = "204--208",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Immunotherapy and biological modifiers for the treatment of malignant brain tumors

AU - Marras, Carlo

AU - Mendola, Carmela

AU - Legnani, Federico Giuseppe

AU - DiMeco, Francesco

PY - 2003/5

Y1 - 2003/5

N2 - The relative ineffectiveness of current therapies for malignant gliomas has led to the need for novel therapeutics. Therapies based on biologic modifiers are among a variety of cancer treatments currently in use or under experimental evaluation and have shown great promise, especially since several potent stimulators of the immune system have been cloned and are now available for clinical use. Early attempts at glioma therapy based on biologic modifiers, however, have failed to demonstrate significant effectiveness. In this review, we select and summarize the results of preclinical and clinical studies published during the past two years that focus on immunotherapy and biologic modifiers for treating gliomas. Despite limited clinical success, we conclude that an increased understanding of molecular biology and immunology from recent studies may pave the way for more effective approaches.

AB - The relative ineffectiveness of current therapies for malignant gliomas has led to the need for novel therapeutics. Therapies based on biologic modifiers are among a variety of cancer treatments currently in use or under experimental evaluation and have shown great promise, especially since several potent stimulators of the immune system have been cloned and are now available for clinical use. Early attempts at glioma therapy based on biologic modifiers, however, have failed to demonstrate significant effectiveness. In this review, we select and summarize the results of preclinical and clinical studies published during the past two years that focus on immunotherapy and biologic modifiers for treating gliomas. Despite limited clinical success, we conclude that an increased understanding of molecular biology and immunology from recent studies may pave the way for more effective approaches.

UR - http://www.scopus.com/inward/record.url?scp=0038686979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038686979&partnerID=8YFLogxK

U2 - 10.1097/00001622-200305000-00004

DO - 10.1097/00001622-200305000-00004

M3 - Article

C2 - 12778012

AN - SCOPUS:0038686979

VL - 15

SP - 204

EP - 208

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -